The aconitate decarboxylase 1/itaconate pathway modulates immune dysregulation and associates with cardiovascular disease markers in SLE

Objective The Krebs cycle enzyme Aconitate Decarboxylase 1 (ACOD1) mediates itaconate synthesis in myeloid cells.. Previously, we reported that administration of 4-octyl itaconate abrogated lupus phenotype in mice. Here, we explore the role of the endogenous ACOD1/itaconate pathway in the development of murine lupus as well as their relevance in premature cardiovascular damage in SLE. Methods We characterized Acod1 protein expression in bone marrow-derived macrophages and human monocyte-derived macrophages, following a TLR7 agonist (imiquimod, IMQ). Wild type and Acod1−/− mice were exposed to topical IMQ for 5 weeks to induce an SLE phenotype and immune dysregulation was quantified. Itaconate serum levels were quantified in SLE patients and associated to cardiometabolic parameters and disease activity. Results ACOD1 was induced in mouse bone marrow-derived macrophages (BMDM) and human monocyte-derived macrophages following in vitro TLR7 stimulation. This induction was partially dependent on type I Interferon receptor signaling and specific intracellular pathways. In the IMQ-induced mouse model of lupus, ACOD1 knockout (Acod1−/−) displayed disruptions of the splenic architecture, increased serum anti-dsDNA and proinflammatory cytokine levels, enhanced kidney immune complex deposition and proteinuria, when compared to the IMQ-treated WT mice. Consistent with these results, Acod1−/− BMDM exposed to IMQ showed higher proinflammatory features in vitro. Itaconate levels were decreased in SLE serum compared to healthy control sera, in association with specific perturbed cardiometabolic parameters and subclinical vascular disease. Conclusion These findings suggest that the ACOD1/itaconate pathway plays important immunomodulatory and vasculoprotective roles in SLE, supporting the potential therapeutic role of itaconate analogs in autoimmune diseases.


Animals and lupus model.
Female wild type (WT) mice and ACOD1 knockout mice (Acod1 -/-) were purchased from Jackson Laboratory (strains JX5304 and JX29340, respectively).Mice were bred under specific pathogen-free conditions and all treatments and experiments were done in accordance with NIH guidelines (NIAMS protocol no.A019-05-03).To induce a lupus phenotype, WT and Acod1 -/-mice (8-10-week-old) were treated with 5% IMQ cream (Fougera) epicutaneously, 3 times per week for 5 weeks.Mice were euthanized 48 to 72 h after the final treatment.Blood was collected by terminal cardiac puncture.Spleens and kidneys were harvested for RNA, protein, and histology.Spleens were smashed through a 70 μM sterile filter to obtain single-cell suspensions, and subsequently analyzed by flow cytometry.Red blood cells (RBCs) were lysed using ammonium-chloride-potassium lysing buffer (3)(4)(5).

Complete blood count (CBC).
CBCs were performed in the NIH Department of Laboratory Medicine.

Histology
Spleen samples were fixed in 10% formalin solution.Tissues were sent to Histoserv, Inc for H&E and PAS staining.Histopathology slides were digitally scanned and analyzed by the Pathology Core Facility, NHLBI.Slides were scored based on histopathological criteria as follow: 0, no changes; 1, mild changes, 2, moderate changes and 3 severe changes.Kidney sections were snap frozen and sent to Histoserv, Inc for sectioning.

Quantification of serum autoantibodies.
Serum total IgG, anti-Sm, anti-RNP and anti-ds DNA quantification were performed by ELISA using commercially available kits from Alpha Diagnostic International.Mice sera were thawed and clarified by centrifugation at 14,000 rpm 10 min, then diluted 1:100 in low-nonspecific binding buffer.Assays were performed following the manufacturer's instructions (6).

Evaluation of immune complex deposition in mouse kidney
For immunofluorescent detection of immune complex deposition, kidneys were perfused with PBS and snap frozen in OCT.Frozen sections were fixed in cold acetone for 10 min and washed with PBS.Slides were blocked with 5% sterile-filtered BSA 1 h at room temperature, then incubated with antibodies diluted in 1% BSA.Samples were washed with PBS and counterstained with 1:10,000 Hoechst.Slides were sealed using Prolong Gold.All images were captured on a Zeiss LSM780 confocal microscope using the same acquisition settings.IgG and C3 were quantified by fluorescence intensity and measured in 10 to 15 independent glomeruli for each mouse using Fiji software.IgG and C3 intensity were subsequently normalized to Hoechst intensity within the same glomerulus to calculate a deposition metric (1).

Proteinuria evaluation.
The urine albumin:creatinine ratio was determined using ELISA kits for creatinine and mouse albumin according to instructions of the manufacturer (EthosBiosciences) (6).

RNA sequencing
RNA was isolated from BMDM exposed or not, to IMQ for 12 hours.Tri Reagent (Sigma-Aldrich) was used followed by column-based purification with RNA Clean & Concentrator-5 Kit (Zymo Research).NEBNext Poly(A) mRNA Magnetic Isolation kit (New England BioLabs) was used to generate cDNA libraries.Picogreen dsDNA quantitation assay (Thermo Fisher Scientific) was used to measure the cDNA concentration; cDNA was diluted to 3 nM, cDNA libraries were pooled together, and RNASeq data were generated with an Illumina Novaseq6000 system (8).

Seahorse analysis of BMDM
Seahorse analysis was performed as previously described (11).The following reagents were used: glucose, oligomycin, carbonyl cyanide-4-(trifluoro-methoxy) phenylhydrazone, 2-deoxy-D-glucose, rotenone, antimycin A, sodium pyruvate (all from Sigma Aldrich), L-glutamine (Agilent), XF calibrant (pH 7.4; Agilent), and XF RPMI medium (pH 7.4; Agilent).Seahorse plates and cartridges were from Agilent.BMDM were plated on Seahorse culture plates (100,000 cells/well) in XF RPMI medium.Analysis was performed at 37°C with no CO2, using an XF-96e analyzer according to instructions of the manufacturer (Agilent).Mitochondrial stress test assay was performed using Seahorse XF RPMI medium with 25 mM glucose, 1 mM sodium pyruvate, and 2 mM Lglutamine.For mitochondrial stress tests, cells were treated serially with oligomycin (5 μM), FCCP (1 μM), rotenone (100 nM), and antimycin A (1 uM), and oxygen consumption rates were quantified.For glycolysis stress tests, same number of cells were suspended in Seahorse XF RPMI medium with 2 mM L-glutamine; cells were treated serially with glucose (25 mM), oligomycin (5 μM), and 2-DG (100 mM), and extracellular acidification rates were measured over time.Cell numbers at assay completion were normalized to DNA content using CyQuant dye (Thermo Fisher Scientific).Wave, Excel, and Graph-Pad Prism software were used to analyze and graph the data (11).

Quantitative real-time PCR
RNA from macrophages was obtained, and gene expression was evaluated by qRT-PCR.
Total RNA was extracted using Tri Reagent (Sigma-Aldrich) and retrotranscribed with the Iscript™ Reverse Transcription Supermix cDNA Synthesis kit (Bio-rad).For qRT-PCR, mRNA levels of selected genes were detected using TaqMan® _Gene Expression Assays (Applied Biosystem Inc.) and results were normalized relative to the expression of TATA-box binding protein (TBP) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA and expressed using the Δ Δ cycle threshold method.Gene expression was quantified using a CFX96 Real-Time PCR System (Bio-rad) (2).

Western blot
Protein lysates were subjected to SDS-PAGE and transferred onto polyvinylidene difluoride membranes (Biorad).Unspecific binding was blocked with 10 % BSA (Sigma Aldrich) for 1h.Membranes were then incubated with antibodies against proteins of interest and incubated with the corresponding secondary IRDye 800 CW antibodies (Licor).Bands were detected using the Odyssey CLx Instrument (2).

Cytokine determination in cell supernatant
Culture supernatants from cells stimulated with TLR agonists were harvested, and release of TNF, IL-1 β, IL-6 was quantified with ELISA kits (BD Biosciences).

Quantification of NETs and mROS.
Isolation of mouse bone marrow neutrophils, quantification of NET formation and mROS were performed as previously described (1

Vascular Functions tests
Lupus patients and healthy had been recruited to a previously described cardiovascular cohort at NIH (13) and underwent various vascular function, coronary artery plaque and vascular wall inflammation, cholesterol efflux capacity assessment and measurement of insulin resistance using HOMA-IR.Briefly, subjects were instructed to abstain from smoking, caffeinated beverages, and fasting for at least 6 hours before testing, withholding medications on the test morning.Testing occurred in a temperature-controlled room with subjects in a supine position.CAVI was measured using VaSera-1500, with cuffs and EKG electrodes placed on arms and ankles.Results were automatically calculated with VaSera VS-1000 software.Peripheral Arterial Tonometry (PAT): Microvascular endothelial function was assessed using EndoPAT 2000.Finger probes were applied bilaterally, and a BP cuff was placed on one arm.With the other arm serving as the control arm.PAT was continuously measured for 20 minutes, and -in between, for 5 minutes -BP cuff was inflated to supra systolic pressure in the test arm.After occlusion dilatation, RH was captured by EndoPAT as an increase in the PAT signal amplitude and compared with the control arm.
A postocclusion/preocclusion ratio was calculated by EndoPAT software, providing a RHI.
CCTA: Performed with a 320-detector row scanner, coronary plaque in major arteries was assessed using QAngio CT.Total (TB), calcified (CB), and noncalcified burden (NCB) indices were calculated.The imaging process included localizer images, coronary calcium score, contrast timing images, and contrast-enhanced images.

Metabolite Sample Preparation
Plasma samples were thawed on ice and precipitated using an equal volume of ice-cold methanol.An equal volume of chloroform was added to each sample.Samples were agitated for 30 minutes at 4 o C and subsequently centrifuged at 16k g for 20 min to induce layering.An aliquot of the top (aqueous) and bottom (organic) layer were collected.The aqueous layer was diluted 5x in 1:1 methanol:water for LCMS injection.For all LCMS methods LCMS grade solvents were used (14).

Measurement of itaconate in serum from SLE patients
Measurement of itaconate serum samples from healthy volunteers and SLE patients was evaluate by Liquid Chromatography Tandem Mass Spectrometry as previously described (15).Briefly, aqueous metabolites were analyzed using a combination of a previously established ion-pairing method operating exclusively in negative ionization mode with modification and a pentafluorophenylpropyl (F5) column method operating exclusively in positive ionization mode (McCloskey, Schwarz, Groveman).Ion-pairing injections were separated using a Sciex ExionLC AC system and measured using a Sciex 5500 QTRAP mass spectrometer.Quality control samples were injected regularly to monitor for signal stability.For negative mode analysis, peaks were resolved with on a Waters Atlantis T3 column (100 Å, 3 μm, 3 mm X 100 mm) with a gradient from 5 mM tributylamine, 5 mM acetic acid in 2% isopropanol, 5% methanol, 93% water (v/v) to 100% isopropanol over

Correlation of serum itaconate levels with vascular function tests.
Vascular function tests were performed as previously described (13).Cardio-ankle vascular index (CAVI), Endopath_RHI, non-calcified burden (NCB), Cholesterol efflux, Body mass index (BMI), vascular inflammation (TB) and Insulin resistance (HOMA IR) were calculated, and each of them correlated to serum itaconate levels.

Statistics.
Data were plotted using GraphPad Prism.Statistical tests for group comparisons were performed as appropriate.For endothelium vasorelaxation assays, two-way analysis of variance with Tukey's correction for multiple comparisons was used.For all other analyses, Mann-Whitney, Kruskal-Wallis analysis or Student's t test were performed to determine significant differences.P values less than or equal to 0.05 were considered significant.or IMQ-treated WT and Acod1 -/-mice.a) Red blood cell count (M/μL), b) Hemoglobin (g/dL), c) Percentage of reticulocytes, d) Platelets (K/μL), e) White blood cells count (K/μL), f) red blood cell morphology by Wright staining, and g) Total number of neutrophils, lymphocytes, monocytes, eosinophils and basophils.Untreated WT and Acod1 -/-conditions, n = 6.IMQ-treated WT and Acod1 -/-conditions, n = 10.Graphs show the mean ± SEM.The statistical analysis was done using Student's t test,*:p<0.05.
).Briefly, BM neutrophils were purified with Percoll gradient.Cells were seeded in 96-well plates (200,000 cells/100 μl/well in CCTA).Pregnant or lactating women, as well as individuals with active infections, were not eligible for participation.Controls were excluded if they had any concurrent medical issues or were taking medications that could potentially interfere with study results.Following enrollment, controls were further excluded if they exhibited HDL <40, BMI >35, diagnosed hypertension, and/or dyslipidemia.All participants underwent a thorough physical examination and provided fasting blood and urine samples before undergoing vascular testing.Laboratory parameters including fasting blood glucose and lipid panel, white blood count with differential, and systemic inflammatory markers were quantified in the clinical laboratory at the NIH: HOMA-IR was calculated as (glucose [nmol/ml] + insulin [μIU/ml])/22.5.
triplicates for each dye) and allowed to form NETs in the presence of Sytox (to quantify extracellular DNA; 1 μM final concentration), Quant-It PicoGreen (to quantify total DNA; stock solution diluted 1:250), and MitoSOX (to quantify mROS; final concentration 200 ng/ml).All dyes were from Thermo Fisher Scientific.At baseline, 1 h, and 2 h, fluorescence was measured for PicoGreen (485 of 520 nm), MitoSOX (510 of 580 nm) and Sytox (485 of 520 nm), respectively, using a FluoStar Omega BMG Labtech plate reader.Cells without dye were used as blanks.